Who Supplies Febuxostat to India from GERMANY

Importing finished pharmaceutical formulations containing Febuxostat into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered prior to import. For formulations under HS Code 30049099, the manufacturer must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT). The registration process involves submitting an application to the Licensing Authority under the Act, which is the Drugs Controller General (India) at CDSCO. The timeline for import drug registration can vary, but it typically takes several months to complete all necessary procedures.

Imported finished pharmaceutical formulations containing Febuxostat must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, and a Certificate of Analysis (CoA) must accompany each shipment. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV, is necessary to demonstrate the product's shelf-life under Indian climatic conditions. The formulations must comply with the standards set by the Indian Pharmacopoeia. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with these requirements.

Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Additionally, bilateral agreements between India and Germany have been established to facilitate pharmaceutical trade, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline import procedures.

India imports finished Febuxostat formulations primarily due to the availability of patented or branded products, specific dosage forms not produced domestically, and the need to meet patient demand for these treatments. The domestic capacity for manufacturing Febuxostat formulations is limited, leading to a dependency on imports to fulfill market requirements. The market size for Febuxostat formulations in India is substantial, with a total export market of $48.9 million across 182 exporters to 91 countries.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The total duty amounts to 17.10%. There are no additional duties such as the National Calamity Contingent Duty (NCCD) or Anti-Dumping Duty applicable to these imports. Exemption notifications are not available for this product category.

India sources finished Febuxostat formulations from Germany due to the country's competitive advantages, including the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Germany's share in the Indian market for these formulations is significant, with two foreign manufacturers/suppliers involved in four shipments valued at $2.7K USD. Other suppliers, such as those from China, the United States, and other European countries, also participate in this market, but Germany's reputation for quality and innovation provides a competitive edge.

India imports finished Febuxostat formulations from Germany due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Germany's advanced pharmaceutical industry offers formulations that meet specific therapeutic needs not addressed by domestic manufacturers.

Compared to other origins like China, the European Union, and the United States, Germany offers superior quality, regulatory compliance, and reliability in pharmaceutical manufacturing. While other countries may offer lower prices, Germany's commitment to quality and innovation provides a unique advantage in the market.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to global supply chain issues, highlighting the need for strategic planning.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate single-source risk.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) or Documents Against Payment (DA/DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with demand forecasts to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance.

1. 1DGFT Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organization.
3. 3Form 40/41: Submit the necessary forms for import registration.
4. 4Drug Import License: Acquire a license for importing drugs.
5. 5No Objection Certificate (NOC): Obtain NOC from the Directorate General of Foreign Trade.
6. 6Customs Broker: Engage a licensed customs house agent for clearance.
7. 7Advance Ruling: Seek an advance ruling for HS Code 30049099 if necessary.

1. 1Certificate of Analysis (CoA): Verify product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Confirm regulatory compliance.
3. 3Good Manufacturing Practice (GMP) Certificate: Ensure manufacturing standards.
4. 4Drug Master File (DMF): Provide detailed product information.
5. 5Stability Data: Dem